Opinions

HIMS (stock, NYSE)

The recent aggressive sell-off is considered likely overdone, making the stock cheap, and its underlying numbers don't look that bad.

ORCL (stock, NYSE)

Showing an aggressive 9% rebound, likely because the market is starting to price in the anticipated $100 billion OpenAI deal.

PLTR (stock, NYSE)

Showing a nice rebound from its lows, indicating a recovery from recent price declines.

AMD (stock, NASDAQ)

The stock is rebounding, likely because the market is starting to price in the anticipated $100 billion OpenAI deal.

NVDA (stock, NASDAQ)

Positioned to benefit from a $3.4 billion chip purchase and lease deal being arranged by Apollo for XAI.

TSLA (stock, NASDAQ)

Considered 'discount shopping' in the low $400s, but investment requires strong belief in its robotics and robo-taxi missions.

RBLX (stock, NYSE)

The company is not expected to be profitable until 2028, making it sensitive to economic downturns, despite having potential enthusiasm in a bull market.

MSFT (stock, NASDAQ)

The stock is rebounding, likely because the market is starting to price in the anticipated $100 billion OpenAI deal.

Topics

Market Recovery and Economic Catalysts

Impact of GLP-1 Drugs on HIMS

Apollo's Private Credit Deal to Fund Nvidia Chips for XAI

Deal Structuring using Special Purpose Vehicles (SPVs)

Analysis of Individual Stocks (Tesla, Palantir, HIMS, Roblox)

Anticipated OpenAI Deal and its effect on Tech Stocks

Role of Private Credit in Funding AI Hardware